Mar 27 |
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference
|
Mar 12 |
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis
|
Mar 7 |
Earnings Preview: Pliant Therapeutics, Inc. (PLRX) Q4 Earnings Expected to Decline
|
Feb 27 |
Pliant Therapeutics reports Q4 results
|
Feb 27 |
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
|
Feb 26 |
Pliant Therapeutics to Participate in Upcoming Investor Conferences
|
Feb 7 |
Pliant Therapeutics to Participate in Upcoming Investor Events
|
Feb 5 |
HC Wainwright & Co. Maintains Buy Rating for Pliant Therapeutics: Here's What You Need To Know
|
Feb 5 |
Pliant updates data from mid-stage trial for lead asset
|
Feb 4 |
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
|